EHA 2022 | Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL

Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma and the treatment of older patients remains a challenge due to the several toxicities associated with intensive chemotherapy and transplantation. In this video, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some primary results from the Phase III SHINE study (NCT01776840) investigating the use of ibrutinib in combination with bendamustine-rituximab (BR) and rituximab (R) maintenance for the treatment of older patients with MCL. The use of ibrutinib, a first-in-class, oral Bruton’s tyrosine kinase (BTK) inhibitor, has transformed the MCL treatment landscape. This trial enrolled previously untreated patients aged 65 or older and results indicated that the primary endpoint of progression-free survival (PFS) was met, with a 50% improvement observed in the BR and R maintenance arm. Prof. Wang also discusses the safety profile of this combination approach, highlighting some of the treatment-related adverse events (AEs) observed, including neutropenia, rash, and pneumonia. Overall, SHINE is the first Phase III trial showing that the combination of ibrutinib and chemoimmunotherapy is highly effective for older patients with MCL. This press briefing was recorded at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.